DE60002356D1 - Purin-derivate - Google Patents

Purin-derivate

Info

Publication number: DE60002356D1
Authority: DE; Germany
Prior art keywords: purine derivatives; purine; derivatives
Prior art date: 1999-10-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

DE60002356T

Other languages

English (en)

Other versions

DE60002356T2 (de

Inventor

Sandra Marina Monaghan

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pfizer Ltd Great Britain

Original Assignee

Pfizer Ltd Great Britain

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-14

Filing date

2000-10-06

Publication date

2003-05-28

2000-10-06 Application filed by Pfizer Ltd Great Britain filed Critical Pfizer Ltd Great Britain

2003-05-28 Publication of DE60002356D1 publication Critical patent/DE60002356D1/de

2004-02-19 Application granted granted Critical

2004-02-19 Publication of DE60002356T2 publication Critical patent/DE60002356T2/de

2020-10-07 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pulmonology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biochemistry (AREA)
Diabetes (AREA)
Immunology (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Otolaryngology (AREA)
Hematology (AREA)
Psychiatry (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)
Vascular Medicine (AREA)

DE60002356T 1999-10-14 2000-10-06 Purin-derivate Expired - Fee Related DE60002356T2 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB9924363		1999-10-14
GBGB9924363.6A GB9924363D0 (en)	1999-10-14	1999-10-14	Purine derivatives
PCT/IB2000/001444 WO2001027130A1 (en)	1999-10-14	2000-10-06	Purine derivatives

Publications (2)

Publication Number	Publication Date
DE60002356D1 true DE60002356D1 (de)	2003-05-28
DE60002356T2 DE60002356T2 (de)	2004-02-19

Family

ID=10862760

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60002356T Expired - Fee Related DE60002356T2 (de)	1999-10-14	2000-10-06	Purin-derivate

Country Status (50)

Country	Link
US (1)	US6350735B1 (de)
EP (1)	EP1220863B1 (de)
JP (1)	JP3994007B2 (de)
KR (1)	KR20020037774A (de)
CN (1)	CN1151167C (de)
AP (1)	AP1442A (de)
AR (1)	AR023275A1 (de)
AT (1)	ATE238336T1 (de)
AU (1)	AU768308B2 (de)
BG (1)	BG106569A (de)
BR (1)	BR0011776A (de)
CA (1)	CA2387531C (de)
CO (1)	CO5251399A1 (de)
CR (1)	CR6584A (de)
CZ (1)	CZ20021223A3 (de)
DE (1)	DE60002356T2 (de)
DK (1)	DK1220863T3 (de)
DZ (1)	DZ3159A1 (de)
EA (1)	EA004655B1 (de)
EC (1)	ECSP003712A (de)
EE (1)	EE200200193A (de)
ES (1)	ES2193990T3 (de)
GB (1)	GB9924363D0 (de)
GE (1)	GEP20043269B (de)
GT (1)	GT200000172A (de)
HK (1)	HK1047110B (de)
HN (1)	HN2000000204A (de)
HU (1)	HUP0203483A2 (de)
IL (1)	IL146342A0 (de)
IS (1)	IS6165A (de)
MA (1)	MA26828A1 (de)
MX (1)	MXPA02003812A (de)
MY (1)	MY136242A (de)
NO (1)	NO20021692D0 (de)
NZ (1)	NZ515323A (de)
OA (1)	OA12059A (de)
PA (1)	PA8503501A1 (de)
PE (1)	PE20010755A1 (de)
PL (1)	PL354932A1 (de)
PT (1)	PT1220863E (de)
SI (1)	SI1220863T1 (de)
SK (1)	SK4842002A3 (de)
SV (1)	SV2002000198A (de)
TN (1)	TNSN00202A1 (de)
TR (1)	TR200200985T2 (de)
UA (1)	UA66945C2 (de)
UY (1)	UY26397A1 (de)
WO (1)	WO2001027130A1 (de)
YU (1)	YU88901A (de)
ZA (1)	ZA200202849B (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7427606B2 (en) *	1999-02-01	2008-09-23	University Of Virginia Patent Foundation	Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) *	1999-02-01	2008-05-27	University Of Virginia Patent Foundation	Method to reduce an inflammatory response from arthritis
GB0003960D0 (en)	2000-02-18	2000-04-12	Pfizer Ltd	Purine derivatives
US6921753B2 (en)	2000-06-27	2005-07-26	Pfizer Inc	Purine derivatives
GB0015727D0 (en) *	2000-06-27	2000-08-16	Pfizer Ltd	Purine derivatives
GB0022695D0 (en)	2000-09-15	2000-11-01	Pfizer Ltd	Purine Derivatives
AP2003002911A0 (en) *	2001-05-25	2003-12-31	Pfizer	An adenosine A2A receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases.
NZ556354A (en) *	2001-10-01	2008-10-31	Univ Virginia	2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
JP2006515829A (ja) *	2002-04-10	2006-06-08	ユニバーシティオブバージニアパテントファウンデーション	炎症性疾病の処置のための、ａ２ａアデノシン受容体アゴニストの使用
TW200519106A (en)	2003-05-02	2005-06-16	Novartis Ag	Organic compounds
US20050033044A1 (en) *	2003-05-19	2005-02-10	Bristol-Myers Squibb Pharma Company	Methods for preparing 2-alkynyladenosine derivatives
GB0401334D0 (en)	2004-01-21	2004-02-25	Novartis Ag	Organic compounds
GB0411056D0 (en)	2004-05-18	2004-06-23	Novartis Ag	Organic compounds
NZ585697A (en) *	2004-08-02	2011-12-22	Univ Virginia Patent Found	2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
US7576069B2 (en) *	2004-08-02	2009-08-18	University Of Virginia Patent Foundation	2-polycyclic propynyl adenosine analogs having A2A agonist activity
WO2006023272A1 (en) *	2004-08-02	2006-03-02	University Of Virginia Patent Foundation	2-polycyclic propynyl adenosine analogs having a2a agonist activity
GB0424284D0 (en)	2004-11-02	2004-12-01	Novartis Ag	Organic compounds
GB0426164D0 (en)	2004-11-29	2004-12-29	Novartis Ag	Organic compounds
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
WO2006134487A1 (en) *	2005-06-15	2006-12-21	Pfizer Limited	3-phenylazetidine derivatives as dopamine agonists
CN100352823C (zh) *	2005-08-19	2007-12-05	浙江车头制药有限公司	一种腺嘌呤衍生物的制备方法
KR20080049113A (ko)	2005-10-21	2008-06-03	노파르티스 아게	Ｉｌ-13에 대항한 인간 항체 및 치료적 용도
GB0601951D0 (en)	2006-01-31	2006-03-15	Novartis Ag	Organic compounds
WO2007092936A2 (en) *	2006-02-08	2007-08-16	University Of Virginia Patent Foundation	Method to treat gastric lesions
US8178509B2 (en)	2006-02-10	2012-05-15	University Of Virginia Patent Foundation	Method to treat sickle cell disease
US8188063B2 (en) *	2006-06-19	2012-05-29	University Of Virginia Patent Foundation	Use of adenosine A2A modulators to treat spinal cord injury
KR20090073121A (ko)	2006-09-29	2009-07-02	노파르티스 아게	Ｐｉ3ｋ 지질 키나제 억제제로서의 피라졸로피리미딘
BRPI0718266A2 (pt)	2006-10-30	2014-01-07	Novartis Ag	Compostos heterocíclicos como agentes anti-inflamatórios.
US8058259B2 (en) *	2007-12-20	2011-11-15	University Of Virginia Patent Foundation	Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
PT2231642E (pt)	2008-01-11	2014-03-12	Novartis Ag	Pirimidinas como inibidores de quinase
US20110281917A1 (en)	2009-01-29	2011-11-17	Darrin Stuart	Substituted Benzimidazoles for the Treatment of Astrocytomas
US8389526B2 (en)	2009-08-07	2013-03-05	Novartis Ag	3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
WO2011018454A1 (en)	2009-08-12	2011-02-17	Novartis Ag	Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
IN2012DN01961A (de)	2009-08-17	2015-08-21	Intellikine Llc
MX2012002179A (es)	2009-08-20	2012-03-16	Novartis Ag	Compuestos heterociclicos de oxima.
WO2012034095A1 (en)	2010-09-09	2012-03-15	Irm Llc	Compounds and compositions as trk inhibitors
UY33597A (es)	2010-09-09	2012-04-30	Irm Llc	Compuestos y composiciones como inhibidores de la trk
WO2012107500A1 (en)	2011-02-10	2012-08-16	Novartis Ag	[1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en)	2011-02-23	2012-08-30	Intellikine, Llc	Heterocyclic compounds and uses thereof
WO2012116217A1 (en)	2011-02-25	2012-08-30	Irm Llc	Compounds and compositions as trk inhibitors
US9062045B2 (en)	2011-09-15	2015-06-23	Novartis Ag	Triazolopyridine compounds
WO2013078440A2 (en)	2011-11-23	2013-05-30	Intellikine, Llc	Enhanced treatment regimens using mtor inhibitors
MX371119B (es)	2012-04-03	2020-01-17	Novartis Ag	Productos de combinacion con los inhibidores de cinasa de tirosina y su uso.
WO2014151147A1 (en)	2013-03-15	2014-09-25	Intellikine, Llc	Combination of kinase inhibitors and uses thereof
TW201605450A (zh)	2013-12-03	2016-02-16	諾華公司	Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (en)	2014-07-25	2016-01-28	Novartis Ag	Combination therapy
MX373272B (es)	2014-07-31	2020-04-16	Novartis Ag	Terapia de combinacion.
EP3801069A4 (de)	2018-06-01	2022-03-16	Cornell University	Kombinationstherapie für eine pi3k-assoziierte erkrankung oder störung
TW202140550A (zh)	2020-01-29	2021-11-01	瑞士商諾華公司	使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5536419A (en) *	1978-09-08	1980-03-14	Yamasa Shoyu Co Ltd	2-substituted adenosine derivative and its preparation
AU8276187A (en) *	1986-10-31	1988-05-25	Warner-Lambert Company	Selected n6-substituted adenosines having selective a2 binding activity
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5877180A (en) *	1994-07-11	1999-03-02	University Of Virginia Patent Foundation	Method for treating inflammatory diseases with A2a adenosine receptor agonists
GB9711643D0 (en)	1997-06-05	1997-07-30	Janssen Pharmaceutica Nv	Glass thermoplastic systems
WO2000023457A1 (en) *	1998-10-16	2000-04-27	Pfizer Limited	Adenine derivatives

1999
- 1999-10-14 GB GBGB9924363.6A patent/GB9924363D0/en not_active Ceased
2000
- 2000-09-14 HN HN2000000204A patent/HN2000000204A/es unknown
- 2000-09-26 PA PA20008503501A patent/PA8503501A1/es unknown
- 2000-10-06 EE EEP200200193A patent/EE200200193A/xx unknown
- 2000-10-06 BR BR0011776-5A patent/BR0011776A/pt not_active IP Right Cessation
- 2000-10-06 TR TR2002/00985T patent/TR200200985T2/xx unknown
- 2000-10-06 CA CA002387531A patent/CA2387531C/en not_active Expired - Fee Related
- 2000-10-06 EA EA200101107A patent/EA004655B1/ru not_active IP Right Cessation
- 2000-10-06 EP EP00964566A patent/EP1220863B1/de not_active Expired - Lifetime
- 2000-10-06 WO PCT/IB2000/001444 patent/WO2001027130A1/en not_active Ceased
- 2000-10-06 KR KR1020027004748A patent/KR20020037774A/ko not_active Abandoned
- 2000-10-06 AP APAP/P/2002/002478A patent/AP1442A/en active
- 2000-10-06 YU YU88901A patent/YU88901A/sh unknown
- 2000-10-06 DK DK00964566T patent/DK1220863T3/da active
- 2000-10-06 IL IL14634200A patent/IL146342A0/xx unknown
- 2000-10-06 MX MXPA02003812A patent/MXPA02003812A/es active IP Right Grant
- 2000-10-06 ES ES00964566T patent/ES2193990T3/es not_active Expired - Lifetime
- 2000-10-06 PL PL00354932A patent/PL354932A1/xx not_active Application Discontinuation
- 2000-10-06 SK SK484-2002A patent/SK4842002A3/sk unknown
- 2000-10-06 GE GEAP20006243A patent/GEP20043269B/en unknown
- 2000-10-06 AT AT00964566T patent/ATE238336T1/de not_active IP Right Cessation
- 2000-10-06 HK HK02108605.8A patent/HK1047110B/zh not_active IP Right Cessation
- 2000-10-06 NZ NZ515323A patent/NZ515323A/en unknown
- 2000-10-06 SI SI200030102T patent/SI1220863T1/xx unknown
- 2000-10-06 DE DE60002356T patent/DE60002356T2/de not_active Expired - Fee Related
- 2000-10-06 AU AU75488/00A patent/AU768308B2/en not_active Ceased
- 2000-10-06 CZ CZ20021223A patent/CZ20021223A3/cs unknown
- 2000-10-06 OA OA1200200102A patent/OA12059A/en unknown
- 2000-10-06 DZ DZ003159A patent/DZ3159A1/xx active
- 2000-10-06 PT PT00964566T patent/PT1220863E/pt unknown
- 2000-10-06 HU HU0203483A patent/HUP0203483A2/hu unknown
- 2000-10-06 UA UA2002042943A patent/UA66945C2/uk unknown
- 2000-10-06 JP JP2001530348A patent/JP3994007B2/ja not_active Expired - Fee Related
- 2000-10-06 CN CNB008096287A patent/CN1151167C/zh not_active Expired - Fee Related
- 2000-10-12 MY MYPI20004790A patent/MY136242A/en unknown
- 2000-10-12 CO CO00077985A patent/CO5251399A1/es not_active Application Discontinuation
- 2000-10-12 GT GT200000172A patent/GT200000172A/es unknown
- 2000-10-12 EC EC2000003712A patent/ECSP003712A/es unknown
- 2000-10-13 TN TNTNSN00202A patent/TNSN00202A1/fr unknown
- 2000-10-13 AR ARP000105421A patent/AR023275A1/es unknown
- 2000-10-13 PE PE2000001098A patent/PE20010755A1/es not_active Application Discontinuation
- 2000-10-13 SV SV2000000198A patent/SV2002000198A/es unknown
- 2000-10-13 UY UY26397A patent/UY26397A1/es not_active Application Discontinuation
- 2000-10-16 US US09/688,624 patent/US6350735B1/en not_active Expired - Fee Related
2001
- 2001-11-16 IS IS6165A patent/IS6165A/is unknown
2002
- 2002-02-08 CR CR6584A patent/CR6584A/es not_active Application Discontinuation
- 2002-04-02 BG BG106569A patent/BG106569A/xx unknown
- 2002-04-09 MA MA26590A patent/MA26828A1/fr unknown
- 2002-04-10 NO NO20021692A patent/NO20021692D0/no not_active Application Discontinuation
- 2002-04-11 ZA ZA200202849A patent/ZA200202849B/xx unknown

Also Published As

Publication number	Publication date
PA8503501A1 (es)	2002-02-21
BG106569A (en)	2002-12-29
CO5251399A1 (es)	2003-02-28
BR0011776A (pt)	2002-03-12
EP1220863B1 (de)	2003-04-23
JP3994007B2 (ja)	2007-10-17
HK1047110B (zh)	2005-03-04
NZ515323A (en)	2003-10-31
MXPA02003812A (es)	2002-09-30
OA12059A (en)	2006-05-03
CA2387531C (en)	2006-12-05
DE60002356T2 (de)	2004-02-19
AP1442A (en)	2005-06-29
KR20020037774A (ko)	2002-05-22
GB9924363D0 (en)	1999-12-15
NO20021692L (no)	2002-04-10
ZA200202849B (en)	2003-06-25
UY26397A1 (es)	2001-05-31
CA2387531A1 (en)	2001-04-19
DK1220863T3 (da)	2003-08-11
HN2000000204A (es)	2001-06-21
IL146342A0 (en)	2002-07-25
AP2002002478A0 (en)	2002-06-30
CZ20021223A3 (cs)	2003-05-14
TR200200985T2 (tr)	2002-10-21
MY136242A (en)	2008-08-29
SI1220863T1 (en)	2003-10-31
ECSP003712A (es)	2002-05-23
IS6165A (is)	2001-11-16
AU7548800A (en)	2001-04-23
UA66945C2 (uk)	2004-06-15
PL354932A1 (en)	2004-03-22
GEP20043269B (en)	2004-06-25
TNSN00202A1 (fr)	2005-11-10
HK1047110A1 (en)	2003-02-07
GT200000172A (es)	2002-04-05
PE20010755A1 (es)	2001-07-17
AU768308B2 (en)	2003-12-04
CN1151167C (zh)	2004-05-26
US6350735B1 (en)	2002-02-26
ES2193990T3 (es)	2003-11-16
CR6584A (es)	2004-01-14
JP2003511459A (ja)	2003-03-25
SK4842002A3 (en)	2003-06-03
CN1358192A (zh)	2002-07-10
MA26828A1 (fr)	2004-12-20
EA200101107A1 (ru)	2002-10-31
NO20021692D0 (no)	2002-04-10
HUP0203483A2 (hu)	2003-02-28
EE200200193A (et)	2003-06-16
EP1220863A1 (de)	2002-07-10
AR023275A1 (es)	2002-09-04
SV2002000198A (es)	2002-02-05
WO2001027130A1 (en)	2001-04-19
PT1220863E (pt)	2003-07-31
YU88901A (sh)	2004-09-03
ATE238336T1 (de)	2003-05-15
DZ3159A1 (fr)	2001-04-19
EA004655B1 (ru)	2004-06-24

Publication	Publication Date	Title
ATE321065T1 (de)	2006-04-15	Purin-derivate
DK1220863T3 (da)	2003-08-11	Purinderivater
IS6196A (is)	2001-12-11	Púrín afleiður
NO20010743D0 (no)	2001-02-14	Antivirale indoloksoacetyl-piperazin-derivater
ATE325807T1 (de)	2006-06-15	Purinderivate
DK1296996T3 (da)	2004-08-16	Purinderivater
NO20000885L (no)	2000-08-25	4-Fenyl-pyridin-derivater
DE60009747D1 (de)	2004-05-13	Admantan-derivate
DE50010060D1 (de)	2005-05-19	Thiazolylamid-derivate
ATE257148T1 (de)	2004-01-15	Propargyletherderivate
ATE273272T1 (de)	2004-08-15	Mevinolinderivate
ATE374747T1 (de)	2007-10-15	Monofluoralkylderivate
DK1187815T3 (da)	2006-06-19	4-phenyl-pyrimidinderivater
DE60006703D1 (de)	2003-12-24	4-hydroxybiphenylhydrazid-derivate
ATE293592T1 (de)	2005-05-15	Resorcinderivate
DE60025348D1 (de)	2006-03-30	Ethansulfonyl-piperidin-derivate
DE60001736D1 (de)	2003-04-24	1-trifluorotmethyl-4-hydroxy-7-piperidinyl-aminomethylchroman-derivate
ATE269328T1 (de)	2004-07-15	1-cycloalkylpyrazolyl-benzoyl-derivate
DK1090019T3 (da)	2005-02-07	Adenosinderivater

Legal Events

Date	Code	Title	Description
2004-05-19	8364	No opposition during term of opposition
2009-08-20	8339	Ceased/non-payment of the annual fee